Sana Biotechnology (SANA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.39
- EPS estimate
- −$0.20
- EPS surprise
- −94.32%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 11, 2025
Sana Biotechnology's latest results in the table are for Q2 2025, reported on August 11, 2025. The loss was $0.39 per share, against an estimated $0.20 loss, a 94.32% miss. That was wider than the $0.21 loss in both Q1 2025 and Q2 2024. The table lists no revenue and no revenue estimates for any quarter.
Sana reported a loss in every quarter shown except Q3 2023, which the table records at $0.00 per share. The annual loss narrowed from $2.79 per share in 2021 to $1.52 in 2022 and $1.16 in 2024. The largest quarterly loss in the table was $1.50 in Q1 2021. Through 2024 and early 2025, quarterly losses stayed between $0.21 and $0.49 per share, and the Q2 2025 loss was the widest since Q1 2024. Sana beat the EPS estimate in 12 of the 19 quarters shown, and missed in the other seven.
The table has no results after Q2 2025. In earlier years, Sana reported third-quarter results in early November and fourth-quarter results between late February and late March. Newer rows will show whether losses return to the narrower range of 2024.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 11, 2025 | −$0.20 | −$0.39 | −94.32% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.22 | −$0.21 | +4.24% | $0.00 | SEC |
| Q4 2024 | Mar 17, 2025 | −$0.25 | −$0.21 | +14.50% | $0.00 | SEC |
| Q3 2024 | Nov 8, 2024 | −$0.26 | −$0.25 | +2.76% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.29 | −$0.21 | +28.08% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$0.30 | −$0.49 | −62.52% | $0.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.38 | −$0.45 | −17.10% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.45 | $0.00 | +100.00% | $0.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.43 | −$0.59 | −38.17% | $0.00 | SEC |
| Q1 2023 | May 8, 2023 | −$0.44 | −$0.43 | +1.80% | $0.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.48 | −$0.40 | +16.67% | $0.00 | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.48 | −$0.48 | +0.97% | $0.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.51 | −$0.47 | +7.41% | $0.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.47 | −$0.17 | +64.19% | $0.00 | SEC |
| Q4 2021 | Mar 16, 2022 | −$0.25 | −$0.60 | −140.00% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.49 | −$0.37 | +25.18% | $0.00 | SEC |
| Q2 2021 | Aug 4, 2021 | −$0.45 | −$0.32 | +29.28% | $0.00 | SEC |
| Q1 2021 | May 5, 2021 | −$0.95 | −$1.50 | −57.15% | $0.00 | SEC |
| Q4 2020 | Mar 24, 2021 | −$0.13 | −$0.60 | −361.54% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Sana Biotechnology (SANA) last report earnings?
Sana Biotechnology last reported on Aug 11, 2025, covering fiscal Q2 2025.
Did SANA beat earnings estimates?
No. Sana Biotechnology reported EPS of −$0.39 for Q2 2025 against a −$0.20 estimate — a 94.32% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.